Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Horizon Taps Yoshihide Okino as VP and Japan GM
Dublin-based Horizon Therapeutics said on June 7 that it has appointed Yoshihide Okino, a maven in the rare disease business, as group vice president and the first general manager of its Japanese arm. Mr Okino has previously held several key…
To read the full story
Related Article
BUSINESS
- Taiho Moves Araris’ ADC into PI for Lymphoma in US
April 30, 2026
- FDA Accepts Zipalertinib NDA for EGFR Exon 20-Mutant Lung Cancer: Taiho
April 30, 2026
- Sandoz Poaches Regeneron’s Yohei Ishii as Japan Chief
April 30, 2026
- Gilead Files Bictegravir Plus Lenacapavir HIV Pill in Japan
April 30, 2026
- Astellas Tops 2 Trillion Yen in Sales, Gears Up for Post-Xtandi Growth
April 28, 2026
AAV (adeno-associated virus) gene therapies are moving beyond rare diseases into more prevalent conditions, with neovascular, or wet, age-related macular…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…